|
Aug 15
|
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
|
|
Apr 27
|
Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
|
|
Apr 26
|
Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update
|
|
Apr 24
|
Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
|
|
Apr 21
|
Tiziana Life Sciences plans to file Investigational New Drug Application for Alzheimer's treatment
|